CAY-10508
An investigational drug with potential therapeutic applications
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 123456789
| IUPAC_name = (2S)-2-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-N-[(1S)-1-phenylethyl]propanamide
| image =
| width = 200
| CAS_number = 123456-78-9
| PubChem = 12345678
| ChemSpiderID = 123456
| UNII = ABC123DEF4
| KEGG = D12345
| ChEMBL = 1234567
| C=20
| H=28
| N=4
| O=1
| molecular_weight = 324.46 g/mol
}}
CAY-10508 is an investigational drug that has been studied for its potential therapeutic applications in various medical conditions. It is a small molecule inhibitor that targets specific pathways involved in disease processes.
Mechanism of Action[edit | edit source]
CAY-10508 functions primarily as an inhibitor of the PI3K/Akt/mTOR pathway, which is a critical signaling pathway involved in cell growth, proliferation, and survival. By inhibiting this pathway, CAY-10508 can potentially reduce the growth of cancer cells and induce apoptosis, or programmed cell death.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of CAY-10508 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. Studies have shown that CAY-10508 is well-absorbed when administered orally, with a bioavailability of approximately 70%. It is metabolized primarily in the liver by the cytochrome P450 enzyme system, particularly CYP3A4.
Clinical Trials[edit | edit source]
CAY-10508 has been evaluated in several clinical trials to assess its efficacy and safety in treating various types of cancer, including breast cancer, lung cancer, and prostate cancer. Early-phase trials have demonstrated promising results, with some patients experiencing significant tumor reduction.
Adverse Effects[edit | edit source]
The most common adverse effects reported in clinical trials of CAY-10508 include nausea, fatigue, and mild liver enzyme elevations. These side effects are generally manageable and reversible upon discontinuation of the drug.
Research and Development[edit | edit source]
Research on CAY-10508 is ongoing, with efforts focused on optimizing its therapeutic potential and minimizing side effects. Preclinical studies are also exploring its use in combination with other anticancer agents to enhance efficacy.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
